PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study of PF-07258669 In Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-07258669
Drug: Placebo
Drug: Midazolam

First Posted Date: 2021-11-09

Last Posted Date: 2024-10-24

Lead Sponsor: Pfizer

Target Recruit Count: 120

Registration Number: NCT05113940

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

Evaluation of the Pharmacokinetics, Safety and Tolerability of Single Dose of PF-06480605 in Chinese Healthy Participants

Phase 1

Completed

Conditions: Inflammatory Bowel Disease

Interventions: Drug: 450mg
Drug: 150mg
Drug: Placebo

First Posted Date: 2021-11-04

Last Posted Date: 2024-03-21

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT05107492

Locations: 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China

Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Ritlecitinib
Drug: Tolbutamide

First Posted Date: 2021-10-28

Last Posted Date: 2023-10-06

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT05097716

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age

Phase 3

Completed

Conditions: RSV

Interventions: Biological: RSVpreF (Group 1)
Biological: RSVpreF (Group 3)
Biological: RSVpreF (Group 2)
Biological: Placebo

First Posted Date: 2021-10-27

Last Posted Date: 2023-04-12

Lead Sponsor: Pfizer

Target Recruit Count: 1028

Registration Number: NCT05096208

Locations: 🇺🇸
Precision Clinical Research, Sunrise, Florida, United States
🇺🇸
Velocity Clinical Research, Providence, East Greenwich, Rhode Island, United States
🇺🇸
East-West Medical Research Institute, Honolulu, Hawaii, United States

and more 15 locations

STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS

Phase 1

Completed

Conditions: Healthy Adults

Interventions: Drug: PF-06882961
Drug: Levonorgestrel & Ethinyl Estradiol
Drug: Atorvastatin
Drug: Midazolam

First Posted Date: 2021-10-26

Last Posted Date: 2024-08-19

Lead Sponsor: Pfizer

Target Recruit Count: 35

Registration Number: NCT05093205

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Elranatamab + lenalidomide + dexamethasone
Drug: Elranatamab + Nirogacestat

First Posted Date: 2021-10-25

Last Posted Date: 2024-11-27

Lead Sponsor: Pfizer

Target Recruit Count: 120

Registration Number: NCT05090566

Locations: 🇺🇸
Cedars-Sinai Tarzana, Tarzana, California, United States
🇺🇸
Banner Gateway Medical Center, Gilbert, Arizona, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 37 locations

This Study is to Describe and Evaluate Patients in Finland Treated With Tofacitinib for the Treatment of Ulcerative Colitis Using Real World Data.

Completed

Conditions: Ulcerative Colitis

First Posted Date: 2021-10-19

Last Posted Date: 2023-03-31

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT05082428

Locations: 🇫🇮
Pfizer, Helsinki, Finland

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

Phase 2

Recruiting

Conditions: Primary Immune Thrombocytopenia

Interventions: Biological: PF-06835375

First Posted Date: 2021-10-07

Last Posted Date: 2024-10-26

Lead Sponsor: Pfizer

Target Recruit Count: 61

Registration Number: NCT05070845

Locations: 🇵🇱
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu, Wroclaw, Poland
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
American Oncology Partners of Maryland, PA, Germantown, Maryland, United States

and more 26 locations

Generate Real World Data On Tofacitinib Induction Therapy and Changes In Clinical and Patient Reported Outcomes.

Terminated

Conditions: Ulcerative Colitis

Interventions: Other: Stool sample collection

First Posted Date: 2021-10-06

Last Posted Date: 2024-10-01

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT05069259

Locations: 🇨🇭
Inselspital Bern, Bern, Bern (de), Switzerland
🇨🇭
Kantonsspital St, Gallen, St. Gallen, Sankt Gallen, Switzerland
🇨🇭
Clarunis, Universitätsspital, Basel, Switzerland

and more 5 locations

A Study of PF-07260437 in Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Breast Neoplasms
Endometrial Neoplasms
Ovarian Neoplasms

Interventions: Drug: PF-07260437
Diagnostic Test: B7-H4 IHC

First Posted Date: 2021-10-05

Last Posted Date: 2024-04-22

Lead Sponsor: Pfizer

Target Recruit Count: 30

Registration Number: NCT05067972

Locations: 🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸
University of Washington Medical Center - Mountlake, Seattle, Washington, United States
🇵🇷
Pan American Center for Oncology Trials- Hospital Oncologico, Rio Piedras, Puerto Rico

and more 12 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy